Key facts
- Abcely’s last known valuation is $2.8M (Sep 2023).
- It has raised $2.6M.
- Notable investors include GO Capital, Angels Santé, Atlanpole, Matwin.
- Status: Privately Held (backing).
Investors
4- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Abcely
- ·The full record, as it builds
Funding rounds
No funding rounds for Abcely are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Abcely
Developer of orally active immunoglobulin-based therapeutic agents designed to address mucosal cancers and inflammatory conditions. The company's product advances a class of immunoglobulin molecules with mucosal tropism, enabling healthcare providers to meet critical needs in oncology and immunotherapy through innovative, precise, and non-invasive treatment methodologies.
- Sector
- Healthcare
- HQ
- Nantes, France
- Founded
- 2022
- Website
- abcely.com/
- Ownership
- Privately Held (backing)
Abcely doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Abcely shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Abcely in its N-PORT filings yet. We sweep new filings monthly.